trial

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

NCTId NCT04432688
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 3,192 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2023-03-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
3,192 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2020-12-01
Primary completion
2023-03-18
Eligibility
ALL

Interventions & indications

Drugs
Lurasidone

Sponsors

Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor

Investigators

1
Yifeng XuPrincipal Investigator

Sites

7 total
Beijing, ChinaHarbin, ChinaChangsha, ChinaJinan, ChinaShanghai, ChinaTaiyuan, ChinaTianjin, China

Facts & assertions

4 sourced
Enrollment
3,192
Phase
NA
Primary Completion Date
2023-03-18
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yifeng Xu
person